Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s
- Eli Lilly: 12 events in the last 90 days
- Previous: earlier the same day · Eli Lilly is partnering with China's InnoCare on a drug deal worth up to $3.35 billion
What happened
As Novo works to turn itself around, some analysts say Lilly has advantages that could help it maintain its position at the top of the obesity drug market.
Summary assembled by rule from the sources below